Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF – Get Free Report) saw strong trading volume on Tuesday . Approximately 8,755 shares traded hands during mid-day trading, an increase of 224% from the previous session’s volume of 2,699 shares.The stock last traded at $46.3750 and had previously closed at $47.30.
Wall Street Analyst Weigh In
Several brokerages have recently weighed in on ZLDPF. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of Zealand Pharma A/S in a research note on Thursday, June 4th. Wells Fargo & Company reaffirmed an “overweight” rating on shares of Zealand Pharma A/S in a report on Thursday, August 13th. Jefferies Financial Group downgraded shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Zacks Research cut shares of Zealand Pharma A/S from a “hold” rating to a “strong sell” rating in a research note on Thursday, August 13th. Finally, Wolfe Research lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Thursday, June 11th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Zealand Pharma A/S currently has a consensus rating of “Hold”.
Check Out Our Latest Analysis on ZLDPF
Zealand Pharma A/S Stock Down 2.7%
Zealand Pharma A/S Company Profile
Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.
Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.
Featured Articles
- Five stocks we like better than Zealand Pharma A/S
- 3 Stocks Built for Higher Rates—And 2 That Could Break
- Safety Stocks Are Not What They Used to Be: 4 Names Built for a Weaker Dollar
- 3 AI Optical Networking Stocks Positioned for the Data Center Buildout
- 5 Defensive Stocks to Watch as CPI and the Fed Put the Rally to the Test
Receive News & Ratings for Zealand Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zealand Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
